Core Viewpoint - NextPlat Corp has launched nationwide medication fulfillment capabilities through a partnership with HealthWarehouse, significantly expanding its healthcare services and market reach beyond Florida, where it currently generates a substantial portion of its revenue [1][3][4]. Group 1: Partnership and Expansion - The collaboration with HealthWarehouse enables NextPlat's PharmcoRx division to fulfill prescriptions and deliver OTC products across all 50 U.S. states, enhancing service offerings and expanding the addressable market [3][4]. - This partnership is expected to support healthcare partners and customers with multi-state operations, accelerating the launch of new e-commerce sites for a broader range of healthcare products and services [3][6]. Group 2: Financial Implications - NextPlat anticipates generating more than 70% of its projected $55 million in annual revenue for 2025 from Florida, indicating a strong reliance on this market prior to the nationwide expansion [3]. - The collaboration is viewed as a transformational step in NextPlat's healthcare growth strategy, aiming to increase revenue and market presence in 2026 and beyond [4][5]. Group 3: Company Background - NextPlat is a global consumer products and services company that provides healthcare and technology solutions through e-commerce and retail channels [8]. - HealthWarehouse operates as a fully licensed digital pharmacy, focusing on increasing access to and reducing costs of healthcare products for consumers nationwide [2][10].

Core Insights - HealthWarehouse.com reported a record year for 2025 with net sales of $49.0 million, reflecting a 46% increase from 2024, driven by an 87% growth in partner services prescription revenues [1][27] - The company achieved a net income of $265,000 and positive cash flow of $1.6 million for the year, indicating a successful operational performance [2][10] Financial Performance - Net sales increased from $33.6 million in 2024 to $49.0 million in 2025, a rise of $15.4 million or 45.8% [6] - Prescription sales reached $46.2 million in 2025, up by $15.3 million or 49.3% compared to 2024, primarily due to growth in partner services [6] - Direct-to-consumer prescription sales declined by 24.3% in 2025, attributed to reduced sales of higher-cost branded medications and increased competition [6] - Over-the-counter net sales increased by 15.9% from $2.2 million in 2024 to $2.5 million in 2025, mainly due to higher marketplace sales [6] Profitability Metrics - Gross profit for 2025 was $17.1 million, a $3.0 million or 21.4% increase from 2024, despite a decrease in gross margin percentage from 42.0% to 35.0% [8] - Selling, general and administrative (SG&A) expenses totaled $16.7 million in 2025, an increase of $2.5 million or 17.7%, but as a percentage of sales, SG&A decreased by 8.2 percentage points to 34.1% [9] - Adjusted EBITDA for 2025 was $1.6 million, up from $1.1 million in 2024, reflecting improved operational efficiency [10] Operational Highlights - The company processed a record number of prescriptions in 2025, contributing to its overall sales growth [2][4] - HealthWarehouse.com continues to invest in proprietary technology to enhance patient experience and operational efficiency [5] - The company anticipates challenges in 2026 due to the end of its authority to dispense high-dollar compounded GLP-1 medications, which may impact sales until new partnerships are established [7]

Core Viewpoint - HealthWarehouse.com reported a 7% decline in sales for Q3 2025, attributed to slowing direct-to-consumer (DTC) sales and shifts in the GLP-1 market [1][19]. Financial Performance - Net sales for Q3 2025 totaled $8.4 million, a decrease of 7% from $9.0 million in Q3 2024 [1][5]. - Year-to-date sales reached $39.1 million, reflecting a 97% increase compared to $19.9 million in the prior year [1][5]. - The company reported a net loss of $72,000 for Q3 2025, compared to a net income of $74,000 in Q3 2024 [10]. - Adjusted EBITDA for Q3 2025 was $343,000, down from $405,000 in Q3 2024 [11]. Sales Breakdown - Prescription sales were $7.7 million for Q3 2025, a decrease of 7.9% from $8.4 million in Q3 2024 [6]. - Over-the-counter product sales increased by 10.8% to $689,000 in Q3 2025, compared to $622,000 in Q3 2024 [7]. Gross Profit and Margins - Gross profit for Q3 2025 was $3.6 million, a decrease of $194,000 from the previous year [8]. - Gross margin percentages were 42.8% for Q3 2025, slightly higher than the previous year, but lower for the nine-month period at 34.0% [8]. Operating Expenses - Selling, general and administrative expenses were $3.6 million for Q3 2025, a slight increase of 0.1% from the previous year [9]. - Year-to-date operating expenses totaled $12.8 million, an increase of 27.6% compared to $10.0 million in the prior year [9]. Management Commentary - The CEO expressed optimism about future growth despite the current sales slowdown, highlighting a strong pipeline of new opportunities and the company's ability to generate positive cash flow [3][4]. - The company continues to invest in proprietary technology to enhance patient experience and operational efficiency [3].